TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02196129
Drug: Sinbaro-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
Study: NCT02196129
Drug: Hwangryun
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
Study: NCT02197156
Drug: 10 mg HC-ER
Normalized name: hydrocortisone 10 MG/ML [Aquanil HC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT02197156
Drug: 30 mg HC-ER
Normalized name: Touro HC 5 MG / 575 MG Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT02197156
Drug: 10 mg HC / 325 mg APAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT02197156
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT00412620
Drug: ABT-925
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00412620
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03561883
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT03561883
Drug: Standard-dose PPIs QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: background therapy
Study: NCT02276677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, intranasal
Study: NCT01369433
Drug: Tivozanib + capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive 1.5 mg of tivozanib once daily for 2 weeks beginning on Day 1, followed by 1 week off. Subjects will receive Capecitabine (Xeloda®) 825 mg/m2 or 1000 mg/m² or 1250 mg/m² oral twice daily. Subjects will receive capecitabine twice daily for 2 weeks beginning on Day 1, followed by 1 week off.
Study: NCT03163966
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral Methotrexate tablets
Study: NCT03163966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral CR6086 Placebo capsules
Study: NCT03805399
Drug: Pyrotinib with Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: If patients were LAR subtype with HER2 gene activated mutation, she would receive pyrotinib(EGFR-TKI) 400mg qd and capecitabine 1000mg/m2 bid (d1-d14)
Study: NCT03805399
Drug: BLIS with anti-VEGFR included therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: If patients were BLIS subtype and did not have a BRCA gene pathogenic mutation , she will receive:~E2: apatinib 250mg qd continuously combined with VP-16 50mg qd (three week on one week off); E3: famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off); E4: BP102 10mg/kg d1,d15 combined with nab-paclitaxel 100mg d1,d8,d,15; q4w
Study: NCT03805399
Drug: MES with anti-VEGFR included therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: If patients were MES subtype and without PI3K/AKT pathway activation,she will receive famitinib 20mg qd continuously combined with VP-16 50mg qd (three week on one week off).
Study: NCT00324155
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous solution; intravenous; 0 mg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24; until disease progression, unacceptable toxicity or withdrawal of consent
Study: NCT03314025
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peri-operative therapy of a Placebo oral capsule daily for a total of 7 days.
Study: NCT00009997
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00009997
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00049569
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IT
Study: NCT00049569
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00049569
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00049569
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00049569
Drug: therapeutic hydrocortisone
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IT
Study: NCT01756703
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for 8 weeks
Study: NCT00888745
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and subcutaneous ascending dose
Study: NCT00888745
Drug: PRO283698
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous and subcutaneous ascending dose
Study: NCT00315549
Drug: Telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002791
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00117819
Drug: [123I]ß CIT and SPECT imaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: To assess \[123I\]ß CIT and SPECT imaging
Study: NCT04525820
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient receives a single dose of a placebo solution
Study: NCT03274817
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
Study: NCT00399750
Drug: fluoropyrimidine
Normalized name: Fluoropyrimidine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03137537
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procedure prescribed to compare the active effect of a medicine.
Study: NCT03218592
Drug: Truvada Pill
Normalized name: Truvada Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
Study: NCT03338010
Drug: LY2963016
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03338010
Drug: Lantus®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01601730
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching oral placebo capsules as control (Treatment 1: Modafinil 0 + Escitalopram 0).
Study: NCT03210766
Drug: THC/CBD
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02098772
Drug: Custodiol-N
Normalized name: N-ethylurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
Study: NCT02098772
Drug: Custodiol
Normalized name: CUSTODIOL HTK SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
Study: NCT00262925
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or orally
Study: NCT00262925
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00262925
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT02504164
Drug: No premedication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No premedication before sedation for endoscopic submucosal dissection
Study: NCT02105090
Drug: Anesthetics, Local
Normalized name: ANESTHETICS, LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03040531
Drug: Alendronate Oral Tablet
Normalized name: alendronate Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg/week in tablets
Study: NCT02760888
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Women will receive oral Diclofenac 100mg 1 hour before the procedure
Study: NCT02760888
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Women will receive a Placebo 1 hour before the procedure
Study: NCT04659109
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration
Study: NCT00097695
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection, matched to study drug Single dose: 3 mL
Study: NCT01508936
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo administered by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
Study: NCT03091439
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received an antibiotic consistent with standard of care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment was 4-6 weeks.
Study: NCT03229499
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo tablet
Study: NCT04075149
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone is an androgen-receptor commonly used (off-label) for hyperandrogenism in girls and women. It is used in this study to determine if androgen blockade can improve ovulation rates in girls with androgen excess, who often have low rates of ovulation in the years following menarche. The spironolactone dose will be as follows: If ≤ 60 kg, 50 mg twice daily; if \> 60 kg, 100 mg twice daily.
Study: NCT02698293
Drug: Vitamin D3 cholecalciferol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 (cholecalciferol) supplementation (10,000 IU daily) will be provided from 3 days prior through 14 weeks after light delivery for PDT.
Study: NCT01214278
Drug: GArTG
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG); 4 capsules per day; 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
Study: NCT01214278
Drug: EE
Normalized name: Beer
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules (4 per day); 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
Study: NCT02696798
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01860989
Drug: KAE609
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAE609 75mg single dose
Study: NCT01860989
Drug: KAE609
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAE609 150mg single dose
Study: NCT01860989
Drug: KAE609
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAE609 225mg single dose
Study: NCT01860989
Drug: KAE609
Approvals — FDA: no, EMA: no, PMDA: no
Description: KAE609 300mg single dose
Study: NCT04184141
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo candy
Study: NCT01584934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment is started and continued for 6 weeks at patient's home. Patients receive 3 g/night during the first week and 4.5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4.5 g/night for 1 week, followed by 3 g/night for 1 week. The next 2 weeks, patients are not treated.
Study: NCT02787278
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same dosage of SP8203. Placebo will be intravenously administered twice daily (intervals of 12 hours)
Study: NCT02218164
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Drug administration will be on an outpatient basis. Capecitabine will be administered at an initial dose of 800 mg/m\^2 by mouth twice daily on days 1-14 of a 21 day cycle with days 15-21 off. This cycle will be repeated every 21 days during the study for a maximum of 9 cycles as tolerated. Administration via feeding tube in patients unable to swallow is permitted.
Study: NCT02251847
Drug: Rosuvastatin/Ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin 5mg
Study: NCT00513214
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Part 1, Single IV infusion at one of six dose levels (mg/kg).~* Part 2, Single SC injection at one of three dose levels (mg/kg).~* Part 3, Three biweekly SC injections at one of two dose levels (mg/kg).
Study: NCT01691248
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).~Treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days.
Study: NCT04355468
Drug: Opioid Free Anaesthesia
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before the induction of general anesthesia, a single-shot thoracic paravertebral block (ThPVB) was performed at the Th3-Th4 level. An insulated needle was used, connected to a peripheral nerve stimulator. 0.5% bupivacaine (0.3 ml∙kg-1) was then injected after a negative aspiration test. The efficacy of the blockade was checked after 20 min on both sides of the thorax with a plastic ampoule of saline. A difference in the sensation of cold between the sides of the thorax was assumed to indicate an effective block. Afterwards a continuous intravenous infusion of lidocaine and ketamine was started:~1. immediately after anesthesia induction, lidocaine was administered as an i.v. bolus at a dose of 1.5 mg∙kg-1 and ketamine in an i.v. bolus of 0.35 mg∙kg-1;~2. followed by an infusion of lidocaine 2.0 mg∙kg-1∙h-1 for 2 hours, continued at a dose of 1.2 mg∙kg-1∙h-1, and ketamine infusion 0.2 mg∙kg-1∙h-1 for 2 hours, continued at a dose of 0.12 mg∙kg-1∙h-1.
Study: NCT01669538
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00379340
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00379340
Drug: Doxorubicin Hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01265056
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar Pill is administered similar to the protocol used for the investigational drug.
Study: NCT02580630
Drug: Ultrasound guided injection with Glucocorticosteroid
Normalized name: Marcaine with Epinephrine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml. Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
Study: NCT02580630
Drug: Ultrasound guided injection with local anaestethic
Normalized name: Marcaine with Epinephrine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml of intralipid (for blinding). Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
Study: NCT02518113
Drug: LY3039478
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT02518113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00861809
Drug: GSK962040 25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg
Study: NCT00861809
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo comparator
Study: NCT00861809
Drug: GSK962040 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg
Study: NCT00861809
Drug: GSK962040 1250 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg
Study: NCT03443778
Drug: Nacl 0,9 %
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injectable Solution
Study: NCT01918384
Drug: NPC-14
Normalized name: ALCOHOL 377.5 mL in 500 mL TOPICAL GEL [ANIOSGEL 85 NPC]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPC-14 will be administrated as following steps. The dose of NPC-14 will be calculated and adjusted by a non-blinded medical doctor and/or a non-blinded pharmacist.~* An initial dose of NPC-14 will be half of that calculated by distribution volume：Vd based on patient age for safety reason.~* After the initial administration, the dose of NPC-14 will be adjusted and maintained by actual Vd, therapeutic drug monitoring of peak serum levels of NPC-14
Study: NCT01918384
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
Study: NCT02841774
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg daily (Weeks 2 - 14)
Study: NCT02841774
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20mg daily (Weeks 2 - 14); at Week 6, if AST, AST, and CK \<+1.5 x ULN, and LDL-c is \>60 and decreased by less than 25% compared with week 2, then dose will be increased to rosuvastatin 40mg daily
Study: NCT00990886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily for 12 weeks
Study: NCT01980940
Drug: Etoricoxib 75 mg 4% DMSO Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 75 mg 4% DMSO gel applied topically.
Study: NCT01980940
Drug: Etoricoxib 75 mg 4% PG Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 75 4% PG gel applied topically.
Study: NCT01980940
Drug: Etoricoxib 150 mg 4% DMSO Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 150 mg 4% DMSO gel applied topically.
Study: NCT01980940
Drug: Etoricoxib 150 mg 4% PG Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 150 mg 4% PG gel applied topically.
Study: NCT01980940
Drug: Etoricoxib 163 mg 4% DMSO gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 163 mg 4% DMSO gel applied topically
Study: NCT01980940
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel applied topically.
Study: NCT01980940
Drug: Etoricoxib 50 mg 4% DMSO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 50 mg 4% DMSO gel applied topically.
Study: NCT01980940
Drug: Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo to Etoricoxib 50 mg 4% DMSO gel applied topically.
Study: NCT00987545
Drug: QAX576
Approvals — FDA: no, EMA: no, PMDA: no
Description: QAX576 injection
Study: NCT00987545
Drug: QAX576 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to QAX576 injection
Study: NCT01857856
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eplerenone (inspra; pfizer) one tablet (50mg standard dosis; 25mg reduced dosis) per day
Study: NCT00876421
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo / 12 weeks
Study: NCT03962829
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy participants administrate one capsule of placebo (containing lactose)
Study: NCT00146471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500-2000 mg daily add-on or Placebo Diazepam as needed
Study: NCT01117610
Drug: Placebo (one of medication)
Approvals — FDA: no, EMA: no, PMDA: no
Description: patients in Group C will receive none of medication preoperatively and intraoperatively
Study: NCT02456532
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: six months of nightly placebo
Study: NCT00676871
Drug: MEDI-538
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose one of MEDI 538 as a continuous IV infusion - dose level is 5 mg/m2/24h (Phase 1)
Study: NCT00676871
Drug: MEDI-538
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose two of MEDI 538 as a continuous IV infusion - dose level is 10 mg/m2/24h (Phase 1)
Study: NCT00676871
Drug: MEDI-538
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose three of MEDI 538 as a continuous IV infusion-dose level is 15mg/m2/24h (Phase 1)
Study: NCT00676871
Drug: MEDI-538
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose four of MEDI 538 as a continuous IV infusion - dose level is 30 mg/m2/24h(Phase 1)
Study: NCT00676871
Drug: MEDI-538
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose five of MEDI 538 as a continuous IV infusion - dose level is 45 mg/m2/24h (Phase 1)
Study: NCT00676871
Drug: MEDI-538
Normalized name: Medi-Lyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose six of MEDI 538 as a continuous IV infusion - dose level is 60 mg/m2/24h (Phase 1)
Study: NCT01762787
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 30mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
Study: NCT01762787
Drug: Placebo to aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
Study: NCT01762787
Drug: Placebo to prednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0mg orally once a day over a course of 4 days (starting Day -3) Part 2 only